Narkhede Neha

Director Narkhede sells 80,000 CFLT shares ($2.4M) at $30.59; retains 28.5K shares post-transaction

Director Neha Narkhede sold 80,000 shares of Confluent (CFLT) at $30.59 on 2026-02-13, reducing her holdings by -73.7% from 108.5K to 28.5K shares. The current price of $30.66 is -15.4% below the 52-week high of $36.23, and over the past 90 days the stock has advanced +42.5%. Narkhede's cross-ticker track record shows a 90d well-timed rate of 88.89% across 10 prior sales (negative post-sale returns), but at CFLT specifically, outcomes are more mixed: of 4 measurable prior sales, 3 were well-timed at 90-day mark (stock declined after), but one (2025-09-09) posted a +50.5% 90d return, indicating the stock rose sharply after that sale. This filing contains a derivative conversion; her post-transaction holdings in Table I do not represent her total position. Confluent remains unprofitable with FY net income of $-66.5M against $298.5M in latest quarterly revenue and +21.1% annual growth, creating a context of execution risk in a still-loss-making growth company.

Director Narkhede sells 40,000 CFLT shares at $29.77; prior 5 trades at this ticker show 4 of 5 were well-timed (negative 90d returns).

Director Neha Narkhede sold 40,000 shares of Confluent at $29.77 on 2025-12-08, reducing her stake by 58.4%. Her prior trade history at this ticker reveals a strong timing pattern: 4 of 5 prior sells occurred before periods of stock declines, with 90-day returns of +21.3%, +15.4%, -19.0%, -22.4%, and -24.0%—indicating most recent trades were positioned ahead of weakness. The stock is currently priced at $30.00, down 20.3% from its 52-week high of $37.65, and has risen 27.5% over the past 30 days and 54.2% over 90 days, suggesting a recent recovery phase. Confluence operates with negative net income of $-66,504,000.00 in the latest quarter despite 24.0% annual revenue growth, pointing to profitability challenges. The scale of this 40,000-share reduction, combined with the insider's demonstrated ability to time prior exits at this ticker ahead of downturns, merits close attention to forward guidance and unit economics.

Director Narkhede sells 153.2K CFLT shares ($3.0M) at $19.85; retains 28.5K shares after -84.3% holding reduction.

Director Neha Narkhede sold 153,200 shares of Confluent at $19.85 on 2025-09-09, reducing her holding by 84.3% to 28,549 shares. Her prior five trades at this ticker have all been well-timed at the 90-day mark, with post-sale returns ranging from -11.2% to -34.5%, establishing a consistent pattern of selling before subsequent declines. However, this filing involves a conversion of derivative securities, meaning her true post-transaction position is not fully captured in the Form 4 Table I holdings currently visible—additional derivative positions in Table II require analysis before confirming her total exposure to the company. The sale occurs at a price 48.3% below the 52-week high of $37.65, despite a recent 30-day price gain of 17.4%, and occurs in the context of negative recent profitability: the company reported $-82.0M net income in its latest quarter against $282.3M revenue, though annual growth was +24.0%.

Director Narkhede sells 60,000 CFLT shares (-74.8% of holdings) at $19.96; stock now -47.6% from 52-week high, down -32.8% over 90 days.

Director Neha Narkhede sold 60,000 shares of Confluent at $19.96 on 2025-05-02, reducing her holdings by 74.8% to 20,247 shares post-transaction. The sale occurs with CFLT trading significantly below its 52-week high of $37.65, currently at $19.73 (-47.6% from peak) and down 32.8% over the trailing 90 days. This represents a substantial reduction in insider exposure at depressed valuation levels. Notably, Narkhede's prior five trades at CFLT (all sells across February–March 2025) have shown consistent negative 30-day returns ranging from -19.0% to -27.5%, suggesting a pattern of selling into weakness; however, the company remains unprofitable with $-67.6M net income on $271.1M quarterly revenue, and Narkhede's cross-ticker track record shows a 100.00% 90-day well-timed rate on seven prior sells, indicating her historical sell decisions have preceded stock declines across her broader portfolio activity.

Director Neha Narkhede sells 40,000 shares at $29.75–$31.73 (avg $30.68) on 2025-03-03, retains 20,247 shares post-transaction.

Director Neha Narkhede executed 3 separate sales totaling 40,000 shares for $1,227,310.66 on 2025-03-03, reducing her holdings by 66.4% to 20,247 shares. The sales occurred at prices ($29.75–$31.73, blended average $30.68) below the current price of $32.20 and well below the 52-week high of $37.65, suggesting the insider sold before the recent 11.2% 30-day rally. Confluent remains unprofitable (latest full-year net income was negative) despite 24.0% annual revenue growth, and the director's prior 4 same-ticker trades at this company show measurable outcomes of -9.8% to -11.8% within 30 days—though timing assessment at the 90-day mark is incomplete. The FLAG indicates derivative conversion activity; this is a conversion trade of a specific batch, not a position exit, and the insider retains 20,247 post-transaction shares."

Director Neha Narkhede sells 80,000 CFLT shares for $2.9M at $36.22 avg; holds 20,247 shares post-sale.

Narkhede executed 2 separate sales totaling 80,000 shares for $2,897,500.50, reducing her shareholding by 79.8% to 20,247 shares. The blended average price of $36.22 sits near the 52-week high of $37.65, occurring during a 30-day rally of +30.9% for the stock. However, her prior 2 sales at CFLT on 2024-12-13 each posted negative 30-day returns (-9.8% and -11.8%), and her cross-ticker track record of 2 prior sells averaged -10.8% 30-day returns, suggesting a pattern of poorly-timed selling relative to subsequent stock movements. Against a backdrop of ongoing unprofitability (net income of $-74,144,000.00 for the most recent full fiscal year), this sale represents a material reduction in the director's open-market holdings, warranting scrutiny of whether subsequent price movements validate or contradict her prior execution timing.